Pfizer CEO Albert Bourla gave an optimistic read on Tuesday when asked how he thought the trade levies might be implemented.

Merck is shifting manufacturing for its blockbuster drug Keytruda to a new $1 billion factory in Delaware, doubling down on ...

Live stream podcast tomorrow at 12pm ET with Drew Armstrong, Max Bayer & Anna Brown discussing pharma industry's response to ...

The fate of a small, privately-held biotech’s new drug has been delayed, in what appears to be a sign that broad cuts to the ...

In an unlikely partnership between two rivals, Hims & Hers said its members will now be able to get Novo Nordisk’s weight ...

Devoted Health shows growth in 2024 with increased membership and revenue while reducing operating losses, contrasting with ...

Venture-backed Devoted Health seems to be weathering the Medicare Advantage storm, according to an Endpoints News analysis of ...

Pfizer is expanding its multibillion-dollar cost-cutting effort that began in 2023, announcing $1.7 billion in new planned ...

AstraZeneca said it was shutting down a Phase 3 Truqap study in a hard-to-treat form of prostate cancer after an interim ...

Abeona Therapeutics received FDA approval for its cell therapy to treat “butterfly skin,” a rare genetic disease that causes ...

Novartis reports strong Q1 2025 with $13.2B in sales, beating forecasts. Key drugs Xolair, Zolgensma, Kisqali exceed ...

Octagon Therapeutics, led by CEO Isaac Stoner, is shutting down after halting work on B cell immunomodulator and facing ...